Physician profile
Herbert K Mayer
NPI 1447225537
$5,113.11
in general payments reported to CMS, 2019-2025
24 companies · $33.32 in 2025
The $33.32 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $252 · 2021: $878 · 2022: $1,319 · 2023: $1,221 · 2024: $1,191 · 2025: $33.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,425 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.46 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,310.96 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.38 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $402.53 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $305.45 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $294.93 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $173.85 | 2019-2024 | |
| Ardelyx, INC. | $160.37 | 2023-2024 | Ibsrela |
| Janssen Biotech, INC. | $155.27 | 2022-2024 | Stelara, Simponi, Simponi Aria |
| Merck Sharp & Dohme LLC | $149.73 | 2020-2023 | Dificid |
| Genzyme Corporation | $104.74 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $91.09 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $83.49 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $67.69 | 2023-2024 | Voquezna |
| Organon LLC | $56.63 | 2023-2024 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $51.42 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $36.61 | 2023-2024 | Yuflyma, Vegzelma |
| Intercept Pharmaceuticals, INC. | $32.22 | 2023-2024 | Ocaliva |
| Evoke Pharma, INC. | $29.69 | 2021-2022 | |
| Madrigal Pharmaceuticals | $26.71 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $21.62 | 2022 | |
| Concordia Pharmaceuticals INC. | $19.61 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $18.42 | 2024 | Utaswako Afp-L3 |
| Daiichi Sankyo INC. | $13.70 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,169.55 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herbert Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.